Immune Globulin Subcutaneous 16.5% in Treatment of Primary Immunodeficiency: A Two-Year, Multi-Center Analysis

Presented at IgNS 2024

Authors:
Lucinda J. Van Anglen, PharmD
Miren Patel, PharmD
Christina J. Weeks, PharmD
Richard F. Herrscher, MD, FACAAI
Jeffrey W. Langford, MD, AE-C
Precious A. Anyanwu, PharmD, PhD